Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-05-06
2008-05-06
Stockton, Laura L. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S493000, C548S494000
Reexamination Certificate
active
11391893
ABSTRACT:
This invention provides compounds of the formula:wherein: X is a chemical bond, —CH2— or —C(O)—; R1is alkyl, cycloalkyl, —CH2-cycloalkyl, pyridinyl, —CH2-pyridinyl, phenyl or benzyl; R2is H, alkyl, cycloalkyl, —CH2-cycloalkyl, or perfluoroalkyl; R3is H, halo, alkyl, perfluoroalkyl, alkoxy, cycloalkyl, —CH2-cycloalkyl, —NH2, or —NO2; R4is optionally substituted phenyl, benzyl, benzyloxy, pyridinyl, or —CH2-pyridinyl, or the salt or ester forms thereof, as well as methods for using the compounds as inhibitors of plasminogen activator inhibitor-1 (PAI-1) and as therapeutic compositions for treating conditions resulting from fibrinolytic disorders such as deep vein thrombosis and coronary heart disease, and pulmonary fibrosis.
REFERENCES:
patent: 3026325 (1962-03-01), Heinzelman et al.
patent: 3476770 (1969-11-01), Scherrer
patent: 3557142 (1971-01-01), Bell
patent: 3843683 (1974-10-01), Bell
patent: 4478819 (1984-10-01), Hercelin et al.
patent: 4736043 (1988-04-01), Michel et al.
patent: 4851406 (1989-07-01), Mertens et al.
patent: 5164372 (1992-11-01), Matsuo et al.
patent: 5420289 (1995-05-01), Musser et al.
patent: 5482960 (1996-01-01), Berryman et al.
patent: 5502187 (1996-03-01), Ayer et al.
patent: 5541343 (1996-07-01), Himmelsbach et al.
patent: 5612360 (1997-03-01), Boyd et al.
patent: 5859044 (1999-01-01), Dow et al.
patent: 6048875 (2000-04-01), De Nanteuil et al.
patent: 6110963 (2000-08-01), Malamas
patent: 6166069 (2000-12-01), Malamas et al.
patent: 6232322 (2001-05-01), Malamas et al.
patent: 6251936 (2001-06-01), Wrobel et al.
patent: 6302837 (2001-10-01), De Nanteuil et al.
patent: 6479524 (2002-11-01), Priepke et al.
patent: 6599929 (2003-07-01), Cho et al.
patent: 6787556 (2004-09-01), Hargreaves et al.
patent: 6800645 (2004-10-01), Cox et al.
patent: 6800654 (2004-10-01), Mayer et al.
patent: 6844358 (2005-01-01), Malamas et al.
patent: 2003/0013732 (2003-01-01), Elokdah
patent: 2003/0018067 (2003-01-01), Elokdah et al.
patent: 2003/0060497 (2003-03-01), Gerlach
patent: 2004/0116488 (2004-06-01), Jennings et al.
patent: 2004/0116504 (2004-06-01), Elokdah et al.
patent: 2004/0122070 (2004-06-01), Jennings
patent: 2004/0138283 (2004-07-01), Jennings et al.
patent: 2004/0204417 (2004-10-01), Perez et al.
patent: 2005/0070585 (2005-03-01), Elokdah et al.
patent: 2005/0070587 (2005-03-01), Elokdah et al.
patent: 2005/0070592 (2005-03-01), Gundersen
patent: 2005/0096377 (2005-05-01), Hu
patent: 2005/0113428 (2005-05-01), Gopalsamy et al.
patent: 2005/0113436 (2005-05-01), Elokdah et al.
patent: 2005/0113438 (2005-05-01), Hu et al.
patent: 2005/0113439 (2005-05-01), Hu
patent: 2005/0119296 (2005-06-01), Elokdah et al.
patent: 2005/0119326 (2005-06-01), Havran et al.
patent: 2005/0119327 (2005-06-01), Hu
patent: 2005/0215626 (2005-09-01), Havran et al.
patent: 2006/0020003 (2006-01-01), Commons et al.
patent: 3147276 (1981-11-01), None
patent: 43 38 770 (1995-05-01), None
patent: 19543639 (1997-05-01), None
patent: 19753522 (1999-06-01), None
patent: 0 416 609 (1991-03-01), None
patent: 0 508 723 (1992-10-01), None
patent: 0 512 570 (1992-11-01), None
patent: 0 540 956 (1993-05-01), None
patent: 0 655 439 (1995-05-01), None
patent: 0 759 434 (1997-02-01), None
patent: 0 819 686 (1998-01-01), None
patent: 0 822 185 (1998-02-01), None
patent: 0 955 299 (1999-11-01), None
patent: 1 092 716 (2001-04-01), None
patent: 1 156 045 (2001-11-01), None
patent: 2 244 499 (1975-04-01), None
patent: 2 777 886 (1999-10-01), None
patent: 2 799 756 (2001-04-01), None
patent: 1 321 433 (1973-06-01), None
patent: 94/13637 (1994-06-01), None
patent: 94/14434 (1994-07-01), None
patent: 94/26738 (1994-11-01), None
patent: 95/10513 (1995-04-01), None
patent: 96/06840 (1996-03-01), None
patent: 96/21656 (1996-07-01), None
patent: 96/26207 (1996-08-01), None
patent: 96/32379 (1996-10-01), None
patent: 97/09308 (1997-03-01), None
patent: 97/43260 (1997-11-01), None
patent: 97/48697 (1997-12-01), None
patent: 98/08818 (1998-03-01), None
patent: 99/28297 (1999-06-01), None
patent: 99/43651 (1999-09-01), None
patent: 99/43654 (1999-09-01), None
patent: 99/43672 (1999-09-01), None
patent: 99/46260 (1999-09-01), None
patent: 99/50268 (1999-10-01), None
patent: 99/58519 (1999-11-01), None
patent: 99/61435 (1999-12-01), None
patent: 00/32180 (2000-06-01), None
patent: 00/35919 (2000-06-01), None
patent: 00/46197 (2000-08-01), None
patent: 00/46915 (2000-08-01), None
patent: 00/64876 (2000-11-01), None
patent: 00/64888 (2000-11-01), None
patent: 01/12187 (2001-02-01), None
patent: 02/30895 (2002-04-01), None
patent: 02/072549 (2002-09-01), None
patent: 03/000253 (2003-01-01), None
patent: 03/031409 (2003-04-01), None
patent: 03/068742 (2003-08-01), None
patent: 03/087087 (2003-10-01), None
patent: 2004/052854 (2004-06-01), None
Hino et al., Neuroscience Letters, 297 (2001), pp. 105-108.
U.S. Appl. No. 10/947,711, filed Sep. 23, 2004, Gopalsamy et al.
Aggarwal et al., “A catalytic antibody programmed for torsional activation of amide bond hydrolysis,”Chem. Eur. J., Jan. 25, 2003, 9(13), 3132-3142.
Aznar, J. et al., “Role of Plasminogen Activator Inhibitor Type 1 in the Pathogenesis of Coronary Artery Diseases,”Haemostasis, 1994, 24, 243-251.
Ballantine, J. A., “The Chemistry of bacteria,”Journal of the Chemical Society Abstracts, 1957, pp. 2222-2227.
Biedmond, B. J. et al., “Thrombolysis and Reocclusion in Experimental Jugular Vein and Coronary Artery Thrombosis,”Circulation, 1995, 91, 1175-1181.
Carmeliet, P. et al., “Plasminogen Activator Inhibitor—1 Gene-deficient Mice,”Journal of Clinical Investigation, Dec. 1993, 92, 2756-2760.
Charlton, Peter, “The status of plasminogen activator inhibitor-1 as a therapeutic target,”Expert Opinion On Investigational Drugs, May 1997, 6(5), 539-554.
Crandall, D. L. et al., “Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy,”Journal of Thrombosis and Haemostasis, Mar. 17, 2004, 2, 1422-1428.
Daci, E. et al., “Mice Lacking the Plasminogen Activator Inhibitor 1 are Protected from Trabecular Bone Loss Induced by Estrogen Deficiency,”Journal of Bone and Mineral Research, Nov. 8, 2000, 15(8), 1510-1516.
De Settimo, A. “Reaction of indole with bromine,”J Org Chem, 1970, 35(8), 2546-2551.
Delgado et al.,Journal of Organic Chemistry, 1993, 58(10), 2862-2866.
Dillard R. D. et al. “Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A21. Indole-3-Acetamides”,Journal of Medicinal Chemistry, American Chemical Society, 39(26), 5119-5136, Dec. 1996.
Guzzo, P.R. et al., “Synthesis of a conformationally constrained threonin-valine dipeptide mimetic: design of a potential inhibitor of plasminogen activator inhibitor-1,”Tetrahedron Letters, 2002 43(1), 41-43.
Hipskind, P. A. et al., “Potent and selective 1,2,3-trusubstituted indole NPY Y-1 antagonists,”J Med Chem, 40(23), 3712-3714.
Julia et al., CA 57:49169, 1962.
Krishnamurti, C. et al., “Plasminogen Activator Inhibitor: A Regulator of Ancrod-Induced Fibrin Deposition in Rabbits,”Blood, Mar. 1987, 69(3), 798-803.
Levi, M. et al., “Inhibition of Plasminogen Activator Inhibitor-1 Activity Results in Promotion of Endogenous Thrombolysis and Inhibition of Thrombus Experimental Thrombosis,”Circulation85, 1992, 305-312.
Malamas, M. S. et al., “Antihyperglycemic activity of new 1,2,4-oxadiazolidine-3,5-diones,”Eur. J. Med. Chem., 2001, 36, 31-42.
Malamas, M.S. et al. “Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties,”Journal of Medicinal Chemistry, Apr. 6, 2000, 43 (7), 1293-1310.
Moody et al., CA 120:298300, 1994.
Nordt, T. K. et al., “Differential Regulation by Troglitazone of Plasminogen Activator Inhibitor Type 1 in Human Hepatic and Vascular Cells,”Journal of
Crandall David LeRoy
Elokdah Hassan Mahmound
Jennings Lee Dalton
Li David Zenan
McFarlane Geraldine Ruth
Stockton Laura L.
Straher Michael P.
Wyeth
LandOfFree
Substituted indole acid derivatives as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted indole acid derivatives as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted indole acid derivatives as inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3953692